Tender Risks In Digital Hematology Will Eventually Be Offset By New Applications

Catalysts

About CellaVision

CellaVision develops digital microscopy and software solutions for hematology laboratories worldwide.

What are the underlying business or industry changes driving this perspective?

• Although adoption of digital hematology is gaining traction in the Americas and parts of APAC, CellaVision remains heavily exposed to tender driven public systems in EMEA. Budget pressure from competing public spending and delayed tenders can restrain instrument placements and keep revenue growth uneven.
• The shift toward connected lab networks in the U.S. favors CellaVision's integrated large instruments and DC-1 concept. However, execution depends on Sysmex salesforce training and hospital decision cycles, so any slowdown in converting small labs within integrated health networks could limit mix benefits for revenue and net margins.
• The new Bone Marrow Application and the largest platform software upgrade to date are positioned to increase instrument utilization and throughput. At the same time, the need to train Sysmex globally and build a sales funnel from scratch creates a lag that can defer the expected uplift in software and application revenue and delay operating leverage in earnings.
• Diversification across Southeast Asia and broader APAC demand for RAL classic stain reagents support a wider recurring revenue base. However, the relatively low starting level and logistical challenges in regions such as the Middle East mean that any disruption or slower ramp could limit the contribution to overall revenue and gross margin stability.
• CellaVision continues to invest in the next generation FPM microscopy platform for hematology and potential use in cytology and pathology. The current shift toward earlier stage R&D with lower capitalization and higher expensed costs, however, introduces a risk of compressing EBITDA and net margins if commercialization timelines extend or adoption in adjacent areas is slower than management expects.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on CellaVision compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• The bearish analysts are assuming CellaVision's revenue will grow by 8.6% annually over the next 3 years.
• The bearish analysts assume that profit margins will increase from 18.4% today to 19.6% in 3 years time.
• The bearish analysts expect earnings to reach SEK 182.9 million (and earnings per share of SEK 7.67) by about April 2029, up from SEK 134.1 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as SEK234.0 million.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 21.8x on those 2029 earnings, down from 22.5x today. This future PE is lower than the current PE for the GB Medical Equipment industry at 27.2x.
• The bearish analysts expect the number of shares outstanding to remain consistent over the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.02%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• CellaVision is tightly linked to tender driven public health systems in EMEA, and the comment that European public funding is under pressure from competing defense spending, together with tender delays in markets such as the U.K., points to a risk that digital hematology investments may be pushed out over several years. This would weigh on lab instrument installations and limit revenue growth.
• The business relies heavily on Sysmex as a distribution partner. The recent episode of excess inventory in EMEA, along with ongoing stock imbalances in smaller instruments in the U.S., shows that partner inventory decisions and ERP rollouts can create sudden order gaps that depress instrument sales, keep gross margin volatile and put pressure on EBITDA and earnings.
• The shift toward earlier stage R&D, combined with lower capitalization of development costs, is already visible in R&D expenses of about SEK 30 million in Q1 and lower capitalized development of SEK 12 million versus SEK 18 million a year earlier. This could structurally keep operating expenses higher and compress EBITDA and net margins if new platforms such as FPM and the Bone Marrow Application take longer to scale commercially.
• The growth story increasingly depends on new applications and software, such as the Bone Marrow Application and Software 7.2. Management highlights that global training of Sysmex, building awareness at conferences and creating a sales funnel will take time, so any slower than expected uptake in these solutions would limit the shift toward higher utilization and recurring software revenues and cap earnings growth.
• EMEA remains a key region but is currently affected by inventory adjustments, tighter public budgets and some logistical issues in the Middle East that have already reduced reagent sales by a few million SEK. If these structural and operational frictions persist, they could hold back both instrument and reagent demand, restraining overall revenue and keeping gross margin and earnings below the levels implied by a rising share price.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for CellaVision is SEK140.0, which represents up to two standard deviations below the consensus price target of SEK179.0. This valuation is based on what can be assumed as the expectations of CellaVision's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK211.0, and the most bearish reporting a price target of just SEK140.0.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be SEK935.3 million, earnings will come to SEK182.9 million, and it would be trading on a PE ratio of 21.8x, assuming you use a discount rate of 6.0%.
• Given the current share price of SEK126.4, the analyst price target of SEK140.0 is 9.7% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.